Board summary
Key figures
47,726
Registered population
60.3% aged 18–64
19.1%
Aged 65+
ICB 14.9% · England 17.9%
24.3%
In IMD quintile 1
ICB 40.7% · England 21.0%
~11,363
Core20 residents (est.)
Resident basis; registered basis ~11,728 · see page 3
8,358
Hypertension register
+10.94% in 3 yrs · England +5.60%
463
SMI register
12.5% of Salford (LAD)'s
1,129
COPD register
Reviews +0.49% in 3 yrs
Forecast to 2030
10,395
Hypertension patients, 2030
+2,037 on today
72.7%
QRISK ≥20% on statins, 2030
+3.01pp over 3 yrs
5.3%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews trail Salford and England.
Coverage is 61.7% against 71.6% in Salford and 65.7% in England (1,147 scale gap across 2,997 patients), which may reflect unverified recall differences.
Heart failure reviews declined over three years.
Annual reviews fell 11.0% over 2023 to 2025 (England +8.7%) to 74.1% (England 78.5%), which could reflect recall or template coding differences.
Blood pressure and frail diabetes control lead England.
Hypertension treatment to target reaches 75.8% (England 70.3%) and frail diabetes HbA1c control reaches 90.6% (England 81.9%), showing strong clinical management once reviewed.
Population, age and ethnicity
Patients aged 65+ make up 19.1% of the list, exceeding Salford and England
Swinton PCN serves 47,726 registered patients. Patients aged 65+ make up 19.1% (9,105), above Salford (LAD) (14.4%), NHS Greater Manchester Integrated Care Board (14.9%), and England (17.9%). Working-age adults (18-64) comprise 60.3% (28,795), below Salford (LAD) (64.8%), the ICB (63.3%), and England (62.7%), while children (0-17) represent 20.6% (9,826) (Salford 21.4%, ICB 21.8%, England 19.6%). Roma residents represent 0.1% (Salford 0.2%, ICB 0.1%, England 0.2%) and Gypsy or Irish Traveller residents 0.0% (0.1% across comparators). Age data reflect registered patients, whereas ethnicity uses resident Census estimates.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Salford (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Salford LA) | 2,980 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 90.6% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 59.0% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Salford LA) | 1,510 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Salford LA) | 15.7 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation averages 24.3% across the PCN but spans 47.3 pp between practices
Swinton PCN’s Core20 share is 24.3%, below Salford (LAD) (44.0%) and NHS Greater Manchester ICB (40.7%), but above England (21.0%). Practice concentration spans 47.3 pp, from 1.32% at The Sides Medical Practice to 48.63% (5,948 estimated patients) at Silverdale Medical Practice, with The Lakes Medical Practice at 29.0% (2,891) and The Poplars Medical Practice at 23.71% (2,703). Practice estimates sum to 11,728 against the 11,363 resident estimate, a difference consistent with differing population bases. Outreach should focus on Silverdale Medical Practice where Core20 concentration and volume coincide.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
463
SMI register
0.96% recorded prevalence
303
Learning disability register
0.63% recorded prevalence
10
Care homes, 359 beds
In the PCN catchment
9.2%
Provide unpaid care
Salford (LAD), Census 2021
The PCN records 303 learning disability patients (0.6%, vs Salford 0.5%, ICB 0.6%, England 0.6%) and 463 severe mental illness patients (1.0%, vs Salford 1.1%, ICB 1.1%, England 1.0%), alongside 10 catchment care homes with 359 beds. With learning disability matching England and severe mental illness in line with national levels, sustaining annual reviews alongside care-home liaison may be the primary workload to protect.
Severe mental illness: physical health checks
SMI blood pressure checks reach 82.6% (England 83.4%), spanning 77.9% at Silverdale Medical Practice to 81.7% at The Sides Medical Practice. BMI recording is 85.6% (England 82.1%) and alcohol recording is 83.7% (England 81.8%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,358
Hypertension register
+10.94%
Register growth, 3 yrs
Salford (LAD) +5.45% · England +5.60%
+4.38pp
BP control, under 80
≤140/90 · +5.18pp aged 80+
+2,037
More patients by 2030
Forecast 10,395 (21.36%)
Hypertension case-finding and control
Hypertension prevalence is 17.4% (8,358 patients), above Salford (12.4%), the ICB (14.4%), and England (15.2%), growing +10.9% over 2023 to 2025 (England +5.6%). Treatment to target reaches 75.8% (England 70.3%; Salford 77.6%), and recent blood pressure readings reach 92.3% (England 90.0%). However, annual heart failure reviews including functional capacity assessment cover 74.1% of the 609 patients on the register (1.3% prevalence), lagging England (78.5%), the ICB (80.0%), and Salford (80.7%) after changing by -11.0% over 2023 to 2025 while England rose +8.7%. Strong blood pressure control sits alongside falling heart failure reviews, so prioritising recall for annual functional assessments across the 609 heart failure patients is the immediate clinical priority.
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy reach 66.3% (England 63.6%; ICB 67.0%), though three-year growth (+4.8%) trails England (+6.2%). Among patients aged 65+, lipid-regulating prescribing is 10,661 per 1,000, below Salford (14,002) and England (18,056). Prescribing in older patients sits below Salford and England benchmarks, pointing to an opportunity to audit lipid therapy.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 97,068 | £1.60 | £1.94 | £1.86 | £155,309 |
| Cardiovascular (all), 2025 | 135,733 | £2.76 | £3.15 | £3.33 | £374,623 |
In 2026, the PCN prescribed 97,068 items for lipid-regulating drugs at £1.60 per item (England £1.86; ICB £1.94; Salford £1.54). Across these items, spend was £25,238 less than at England's unit cost. Lower unit cost than England means the PCN spends less per item, offering headroom to expand lipid-regulating coverage without exceeding benchmark spend.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+9.43%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.22%
Asthma prevalence, PCN 3-yr % change
Asthma annual reviews reach 61.7% across the 2,997-patient register, trailing England (65.7%) and Salford (71.6%), representing an unreviewed scale gap of 1,147 patients. Review rates span from 49.9% at The Poplars Medical Practice to 81.4% at The Sides Medical Practice. COPD reviews also trail at 71.7% (England 76.4%). Meanwhile, youth asthma prescribing reaches 1,970 items per 1,000 (England 1,488), youth second-hand smoke recording lags at 74.9% (England 78.8%), and smoking cessation offers fell 4.8 pp over 2023 to 2025 to 91.8% (England +0.1 pp).
Cancer register and children's immunisation
The cancer register comprises 2,026 patients (4.2% prevalence, above England's 3.8% and Salford's 2.9%). In childhood immunisations, Swinton PCN exceeds national benchmarks at age 5 with 94.2% for first-dose MMR and 90.8% for second-dose MMR, showing a 3.4 pp dose difference. Pre-school 4-in-1 booster coverage reaches 81.7%, sitting 13.3 pp below the 95.0% target despite exceeding England (80.9%) and the ICB (80.5%).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, NHS Greater Manchester ICB recorded 55.6% of cancers diagnosed at stage 1 or 2 among cases with a known stage (70.8%), sitting below the 75.0% national ambition by 19.4 pp (2,268.2 extra cases to reach 75.0%). System stage data is not PCN-specific. Swinton PCN's cancer register stands at 4.2% (2,026 patients). Breast screening coverage is 75.1% (England 69.9%), though Silverdale Medical Practice records 68.4%. Cervical screening for women aged 25-49 is 71.2% (England 66.8%), ranging from 67.0% at The Lakes Medical Practice to 78.4% at The Sides Medical Practice. Sustaining screening uptake across practices supports early detection.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
For July 2026 (provisional), Northern Care Alliance NHS Foundation Trust achieved 78.6% on the 62-day referral to treatment standard, below the 85.0% target by 6.4 pp, though above the ICB (75.7%) and England (71.2%). Its 28-day faster diagnosis standard was 75.2% (target 75.0%), trailing England's 79.3%. On 31-day combined treatment, it reached 94.5% against the 96.0% standard. Diagnostic waits show pressure in endoscopy: 40.0% waited 6+ weeks for colonoscopy, 39.9% for flexi sigmoidoscopy, and 36.5% for gastroscopy, while 15.7% waited 6+ weeks across all diagnostic tests. Endoscopy delays at the acute provider could slow lower-gastrointestinal diagnostic pathways.
| Pathways within standard (%) | Northern Care Alliance | Manchester | Bolton | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 75.20 | 80.06 | 80.48 | 79.53 | 79.32 |
| 31-day treatment (96%) | 94.54 | 92.54 | 96.50 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 78.65 | 72.85 | 69.66 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Northern Care Alliance | Manchester | Bolton | England |
|---|---|---|---|---|
| MRI | 5.09 | 11.68 | 2.05 | 21.40 |
| CT | 4.10 | 14.66 | 19.40 | 9.92 |
| Echocardiography | 31.48 | 4.91 | 3.48 | 28.48 |
| Colonoscopy | 40.04 | 4.51 | 1.33 | 30.83 |
| Gastroscopy | 36.48 | 29.35 | 2.06 | 29.02 |
| All 15 DM01 tests | 15.71 | 8.98 | 15.78 | 23.14 |
| Community services activity | Salford residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 37,955 | 573,310 |
| Referrals | 3,340 | 94,470 |
| Patients with a contact | 15,440 | 183,535 |
Community services (residents of Salford), Jun 2026 (provisional). For June 2026 (provisional), adults aged 65+ accounted for 53.9% of borough residents' community service contacts (20,470 of 37,955). In Swinton PCN, registered patients aged 65+ make up 19.1% of the list (9,105 patients). Provider-specific community activity is not captured, but the borough volume demonstrates substantial service demand concentrated in older residents. A heavy community caseload among older people requires coordinated intermediate and primary care management.
Practice variation and patient experience
Clinical QOF achievement reaches up to 100.0% despite an 18.7 pp phone access spread
Overall QOF achievement spans 90.7% at Silverdale Medical Practice to 97.6% at The Sides Medical Practice (England 92.5%). Clinical achievement reaches 99.2% at The Lakes Medical Practice to 100.0% at The Sides Medical Practice (England 97.1%). Vaccination achievement spans 59.6 pp, from 18.9% at Silverdale Medical Practice to 78.5% at The Sides Medical Practice (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Lakes Medical | 110 | 29.0 | 59.9% | 84.7% | 88.0% |
| Silverdale | 119 | 48.6 | 63.7% | 78.3% | 87.5% |
| Sides Medical | 107 | 1.3 | 50.9% | 66.9% | 83.9% |
| Poplars Medical | 106 | 23.7 | 45.1% | 81.5% | 83.8% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Heart failure reviews fell 11.0% over three years while diabetes control rose +16.2%
Over 2023 to 2025, heart failure annual reviews fell 11.0% (England +8.7%, Salford +4.7%), trailing England by 19.8 points. Smoking cessation offers dropped 4.8 pp (England +0.1 pp), and COPD reviews rose +0.5% (England +2.8%). Conversely, breast screening rose +111.0% over 2023 to 2024 (England +8.4%), non-frail diabetes HbA1c control rose +16.2% (England +4.4%), and psychosis alcohol recording rose +12.1 pp (England +5.4 pp). This comparator pattern may reflect recall capacity or recording differences, which a template and recall audit would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Smoking support (SMI)
COPD reviews
QRISK statin treatment
Depression register
Breast screening (53-70)
Diabetes HbA1c control
Alcohol record (psychosis)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Salford (LAD) | Asset | PCN | Salford (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 10 (359 beds) | n/a | Schools (catchment) | 68 | n/a |
| Children's centres | 3 | 16 | Places of worship | 21 | 118 |
| Libraries | 3 | 16 | Primary schools (LA maintained) | 14 | 52 |
| Primary academies | 7 | 21 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma annual reviews cover 61.7% of the 2,997 register (Salford 71.6%, ICB 66.2%, England 65.7%), spanning 49.9% at The Poplars Medical Practice to 81.4% at The Sides Medical Practice (1,147 scale gap). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Heart failure and COPD review recall
Reviews trail England for heart failure (74.1% of 609 vs 78.5%, down 11.0% over 2023 to 2025 vs England +8.7%) and COPD (71.7% of 1,129 vs 76.4%, +0.5% vs +2.8%), while smoking cessation offers fell 4.8 pp to 91.8% (England 94.2%). Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 3
Dementia register and care-home review
Recorded dementia prevalence is 0.6% (274 patients across 47,726 registered), below ICB (0.7%) and England (0.8%) and matching Salford (0.6%), giving an unadjusted benchmark gap of +23 to +99 despite 19.1% (9,105) aged 65+. Low cost, quick to run.
Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.
Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Heart failure functional review recall (p5) | Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs) | — | PCN |
| Pre-school booster recall (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical and breast screening outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · Heart failure and COPD review recall (p12) | COPD register · COPD patients with a review in the last 12 months · Patients with COPD who had a review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
| Option 3 · Dementia register and care-home review (p12) | Registered population · Aged 65+ · Count of Registered Patients aged 65+ | 66.7% diagnosis ambition · 95% care plan 2027 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
